The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 31 March 2026•Updated 1 April 2026•

1 min read

Biogen Announces $5.6 Billion Acquisition to Expand into Immunology and Nephrology

Key Facts

1Biogen announced a $5.6 billion acquisition to add two best-in-class products in immunology and rare diseases.

2 months ago

Version History

3 additional sources confirmed this story

Version 12 months ago

What changed: Identified Apellis Pharmaceuticals as the acquisition target, detailed the specific drugs involved (EMPAVELI and SYFOVRE) with their 2025 sales figures, and added details regarding the contingent value right (CVR) and non-GAAP EPS accretion.

Biogen Inc. (BIIB) has officially identified Apellis Pharmaceuticals as the target of its $5.6 billion acquisition, a move aimed at strengthening its presence in immunology and rare diseases. The transaction includes the acquisition of two key drugs, EMPAVELI® and SYFOVRE®, which generated combined net sales of $689 million in 2025. As part of the deal structure, Biogen has included a contingent value right (CVR) tied to the future sales performance of SYFOVRE®. This strategic expansion allows Biogen to diversify its revenue streams beyond its core neurology business into the high-growth nephrology market. The acquisition is expected to be accretive to Biogen's non-GAAP earnings per share (EPS) starting in 2027. Analysts view this investment as a significant step toward long-term portfolio growth and enhanced shareholder value in the biotech sector.